Ruxolitinib (RUX) is extensively used in myelofibrosis (MF). Despite its early efficacy, most patients lose response over time and, after discontinuation, have a worse overall survival (OS). Currently, response criteria able to predict OS in RUX-treated patients are lacking, leading to uncertainty regarding the switch to second-line treatments. In this study, we investigated predictors of survival collected after six months of RUX in 209 MF patients participating in the real-world ambispective observational RUXOREL-MF study (NCT03959371). Multivariable analysis identified the following risk factors: (i) RUX dose \<20 mg twice daily at baseline, month 3, and 6 (hazard ratio, HR, 1.79, 95\% confidence interval, CI, 1.07-3.0
A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients with Myelofibrosis
Giorgino Toni;
2022
Abstract
Ruxolitinib (RUX) is extensively used in myelofibrosis (MF). Despite its early efficacy, most patients lose response over time and, after discontinuation, have a worse overall survival (OS). Currently, response criteria able to predict OS in RUX-treated patients are lacking, leading to uncertainty regarding the switch to second-line treatments. In this study, we investigated predictors of survival collected after six months of RUX in 209 MF patients participating in the real-world ambispective observational RUXOREL-MF study (NCT03959371). Multivariable analysis identified the following risk factors: (i) RUX dose \<20 mg twice daily at baseline, month 3, and 6 (hazard ratio, HR, 1.79, 95\% confidence interval, CI, 1.07-3.0I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
